tldrdailynews.com logo
Tag

Neurovascular

All articles tagged with #neurovascular

SLIT3 Wiring in Brown Fat Boosts Calorie Burning and Heat Production
science17 days ago

SLIT3 Wiring in Brown Fat Boosts Calorie Burning and Heat Production

A Nature Communications study reveals brown fat uses SLIT3 fragments, produced by BMP1, to drive blood vessel and nerve growth essential for thermogenesis. In mice, removing SLIT3 or its receptor PLXNA1 impairs nerve and vascular networks and lowers heat production, while human fat analyses suggest SLIT3 activity may influence obesity and insulin sensitivity, pointing to therapies that increase energy expenditure rather than curb appetite.

via SciTechDaily|
#brown-fat#neurovascular#obesity
Boston Scientific to acquire Penumbra in $14.5B push into thrombectomy and neurovascular care
business2 months ago

Boston Scientific to acquire Penumbra in $14.5B push into thrombectomy and neurovascular care

Boston Scientific announced a definitive agreement to acquire Penumbra in a cash-and-stock deal valued at about $14.5 billion (Penumbra at $374/share), creating a scaled entry into mechanical thrombectomy and neurovascular therapies. The transaction finances roughly 73% cash and 27% Boston Scientific stock (about $11 billion cash financed with cash on hand and new debt) and is expected to close in 2026 pending stockholder and regulatory approvals. Penumbra reported about $1.4 billion in revenue for 2025. Penumbra stockholders may elect cash or Boston Scientific shares; Adam Elsesser plans to take Boston Scientific stock for all his Penumbra shares. The deal is dilutive to GAAP earnings in the near term and to adjusted EPS in the near term, with accretion expected in later years.

via PR Newswire|
#acquisition#boston-scientific#business
Boston Scientific to acquire Penumbra in $14.5B deal, expanding vascular thrombectomy reach
business2 months ago

Boston Scientific to acquire Penumbra in $14.5B deal, expanding vascular thrombectomy reach

Boston Scientific announced a cash-and-stock deal to acquire Penumbra for about $14.5 billion (Penumbra at $374 per share), expanding its cardiovascular portfolio with Penumbra’s mechanical thrombectomy and neurovascular tech. The transaction is ~73% cash and ~27% stock, financed with cash on hand and new debt, and is expected to close in 2026 after shareholder and regulatory approvals. Penumbra’s 2025 revenue is about $1.4 billion; the deal aims to broaden access to vascular therapies and drive long-term growth, though GAAP earnings are expected to be dilutive in the near term.

via www.bostonscientific.com|
#business#medicaldevices#mergersacquisitions